Home › Trials › NCT06701513

Evaluating the effectiveness of deucravacitinib for plaque psoriasis in adults in France

Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France

Observational Bristol-Myers Squibb · NCT06701513

This study is testing how well deucravacitinib works for adults with moderate-to-severe plaque psoriasis in real life.

Quick facts

Study typeObservational
Enrollment350 (estimated)
Ages18 Years and up
SexAll
SponsorBristol-Myers Squibb Industry-sponsored
Drugs / interventionsdeucravacitinib
Locations40 sites (Amiens and 39 other locations)
Trial IDNCT06701513 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess how effective deucravacitinib is in treating adults with moderate-to-severe plaque psoriasis in real-world settings. Participants will be adults aged 18 and older who are newly starting treatment with deucravacitinib, as reported by their physicians. The study will gather data on treatment outcomes and patient experiences to better understand the drug's effectiveness outside of controlled clinical environments.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with moderate to severe plaque psoriasis and are starting treatment with deucravacitinib.

Not a fit: Patients who are currently participating in or planning to participate in another interventional clinical trial or those with prior treatment experience with deucravacitinib will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of deucravacitinib, potentially improving treatment options for patients with plaque psoriasis.

How similar studies have performed: While this study focuses on real-world effectiveness, similar studies evaluating other psoriasis treatments have shown promising results, indicating that real-world data can be valuable in understanding treatment outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* ≥18 years of age
* Physician-reported diagnosis of moderate to severe plaque psoriasis
* Be newly initiating deucravacitinib
* Do not object to participate

Exclusion Criteria:

* Currently participating in or planning to participate in an interventional clinical trial
* Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial

Where this trial is running

Amiens and 39 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Psoriasis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.